Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2007 1
2008 1
2009 3
2010 2
2011 3
2012 5
2013 1
2014 3
2015 1
2016 3
2017 7
2018 6
2019 9
2020 4
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
Langman CB, Assimos D, Blank M, Calle J, Grauer A, Kausz A, Milliner D, Nazzal L, Smith K, Tasian G, Thompson A, Wood KD, Worcester E, Yang S, Malley MA, Knauf F, Lieske JC; Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup). Langman CB, et al. Among authors: grauer a. Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1637-1644. doi: 10.2215/CJN.0000000000000234. Epub 2023 Jun 21. Clin J Am Soc Nephrol. 2023. PMID: 37342976
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC. Munster PN, et al. Among authors: grauer a. Clin Cancer Res. 2022 Aug 2;28(15):3214-3224. doi: 10.1158/1078-0432.CCR-21-4363. Clin Cancer Res. 2022. PMID: 35583817 Free PMC article. Clinical Trial.
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
Poole KE, Treece GM, Pearson RA, Gee AH, Bolognese MA, Brown JP, Goemaere S, Grauer A, Hanley DA, Mautalen C, Recknor C, Yang YC, Rojeski M, Libanati C, Whitmarsh T. Poole KE, et al. Among authors: grauer a. J Bone Miner Res. 2022 Feb;37(2):256-264. doi: 10.1002/jbmr.4465. Epub 2021 Dec 16. J Bone Miner Res. 2022. PMID: 34738660 Free PMC article.
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML; Foundation for the National Institutes of Health Bone Quality Project. Black DM, et al. Among authors: grauer a. Lancet Diabetes Endocrinol. 2020 Aug;8(8):672-682. doi: 10.1016/S2213-8587(20)30159-5. Lancet Diabetes Endocrinol. 2020. PMID: 32707115
Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Takada J, et al. Among authors: grauer a. J Bone Miner Metab. 2020 Jul;38(4):605. doi: 10.1007/s00774-020-01099-w. J Bone Miner Metab. 2020. PMID: 32198616
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.
Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Maddox J, Grauer A, Bhandari M. Schemitsch EH, et al. Among authors: grauer a. J Bone Joint Surg Am. 2020 Apr 15;102(8):693-702. doi: 10.2106/JBJS.19.00790. J Bone Joint Surg Am. 2020. PMID: 31977817 Free PMC article. Clinical Trial.
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Takada J, et al. Among authors: grauer a. J Bone Miner Metab. 2020 May;38(3):310-315. doi: 10.1007/s00774-019-01057-1. Epub 2019 Nov 9. J Bone Miner Metab. 2020. PMID: 31707465 Clinical Trial.
The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study.
Geusens P, Oates M, Miyauchi A, Adachi JD, Lazaretti-Castro M, Ebeling PR, Perez Niño CA, Milmont CE, Grauer A, Libanati C. Geusens P, et al. Among authors: grauer a. JBMR Plus. 2019 Aug 2;3(10):e10211. doi: 10.1002/jbm4.10211. eCollection 2019 Oct. JBMR Plus. 2019. PMID: 31687647 Free PMC article.
53 results